Invivyd, Inc.

NASDAQ:IVVD

Biotechnology

Healthcare
$0.47 +4.16%

+$0.04 today

Market cap
$138.68M
Beta
0.63
P/E (TTM)
-3.9
EPS (TTM)
-$0.25
52W Low $0.48High $3.07

Volume 6.71M

Average 3.62M

IVVD Common Stock Issued

Cash raised by issuing new shares.

Invivyd, Inc.NASDAQ: IVVD

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued turns negative

Q1 FY2026 common stock issued was -$98K, compared with $10K a year earlier. Trailing-twelve-month common stock issued was $215.74M. Over 3 fiscal years it compounded at +650.6% a year.

Context

  • Common stock issued amounted to 403.6% of revenue in FY2025, up 248.8 pp from a year earlier.
  • Common stock issued increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock issued holds near -$98K or moves back toward the trailing-twelve-month quarterly average of $53.94M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$98K-100.1% QoQ
Last fiscal yearDec 2025
$215.63M+448.9% YoY
LTMMar 2026
$215.74M+71102.0% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1080.0%——
1 year+448.9%——
3-year CAGR+650.6%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
215.63M USD
Year-over-year change
+448.9%
4-year CAGR
-10.2%

Common Stock Issued vs competitors

How IVVD compares with its peers on the latest reported figures

  • IVVD's LTM Mar 2026 common stock issued of $215.74M is the largest of the 10 companies compared; the peer median is $77.76M.
  • Its year-over-year change of +71102.0% is the highest of 9, against a peer median of +262.8%.
  • Common stock issued amounts to 386.2% of revenue for IVVD, versus a peer median of 250.1%.
IVVD Competitors Peer median
Common Stock Issued for IVVD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$215.74M +71102.0%+650.6%386.2%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$126.82M +1104.7%+445.8%363.8%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$118.15M +118.9%+53.5%—
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$90.73M +439.2%-4.5%262.5%
TARAProtara Therapeutics, Inc.LTM Mar 2026$82.4M -40.3%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$77.76M +406.7%-13.1%237.6%
OABIOmniAb, Inc.LTM Mar 2026$28.32M +880.3%-33.5%98.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$24.84M -56.4%-4.4%1274.6%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$19.57M ———
CDXSCodexis, Inc.LTM Mar 2026$16.94M -47.7%+170.3%21.7%
Peer median (excluding IVVD) $77.76M+262.8%-4.4%250.1%

Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(226.79M)(241.32M)(198.64M)(169.93M)(52.49M)
Depreciation & Amortization1K462K2.03M3.11M2.11M
Deferred Income Tax00000
Stock-Based Compensation17.76M21.65M18.69M19.79M11.64M
Change in Working Capital22.79M(16.13M)5.89M(23.47M)(19.69M)
Accounts Receivables000(10.91M)(3.34M)
Inventory000(24.89M)(373K)
Accounts Payables(2.37M)(4.3M)6.47M2.42M3.21M
Other Working Capital25.16M(11.83M)(583K)9.91M(19.2M)
Other Non-Cash Items1.5M15.35M(1.12M)19.79M298K
Operating Cash Flow(184.74M)(219.99M)(173.16M)(170.49M)(58.14M)
Capital Expenditures(84K)(1.71M)(615K)(140K)(155K)
Acquisitions (Net)00000
Purchases of Investments(188.63M)(297.96M)(91.2M)00
Sales of Investments138M69M372.5M00
Other Investing Activities00000
Investing Cash Flow(50.71M)(230.67M)280.68M(140K)(155K)
Debt Repayment00000
Common Stock Issued330.91M510K1.2M39.29M215.63M
Common Stock Repurchased0(4K)(1K)00
Dividends Paid00000
Other Financing Activities(3.39M)510K1.05M46K0
Financing Cash Flow662.68M506K1.05M39.33M215.63M
Effect of Forex Changes0008K0
Net Change in Cash427.24M(450.15M)108.57M(131.29M)157.34M
Free Cash Flow(184.82M)(221.69M)(173.78M)(170.63M)(58.29M)

Invivyd, Inc.

NASDAQ:IVVD

Intrinsic Alpha fair value

Locked

Current Price

$0.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.